Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current Assets
Cash and cash equivalents	$ 91,217	$ 24,165
Accounts receivable, net	1,536	621
Inventories	10,817	7,883
Interest receivable	80	12
Other current assets	9,344	5,335
Total Current Assets	112,994	38,016
Restricted cash	6,389	10,425
Accounts receivable, net of current portion		266
Property and equipment, net	6,670	5,772
Goodwill	71,368	68,697
Other long term assets	192	63
Total Assets	250,251	176,249
Current Liabilities
Accounts payable	3,771	3,984
Accrued expenses	10,974	8,206
Deferred revenue	1,088
Deferred gain on sale of SurgiBot assets	7,500
Contingent consideration – current portion	719	10,502
Notes payable - current portion, net of debt discount	4,788	7,997
Total Current Liabilities	28,840	30,689
Long Term Liabilities
Contingent consideration – less current portion	11,699	12,298
Notes payable - less current portion, net of debt discount	8,385	4,995
Warrant liabilities	14,090
Net deferred tax liabilities	8,389	10,397
Total Liabilities	71,403	58,379
Commitments and Contingencies
Stockholders’ Equity
Common stock $0.001 par value, 750,000,000 shares authorized at December 31, 2017 and 2016, respectively; 199,282,003 and 115,781,030 shares issued at December 31, 2017 and 2016, respectively; and 199,282,003 and 115,687,351 shares outstanding at December 31, 2017 and 2016, respectively	199	115
Additional paid-in capital	621,261	426,609
Accumulated deficit	(447,640)	(302,844)
Treasury stock at cost, 0 and 93,679 shares at December 31, 2017 and 2016, respectively		(241)
Accumulated other comprehensive income (loss)	5,028	(5,769)
Total Stockholders’ Equity	178,848	117,870
Total Liabilities and Stockholders’ Equity	250,251	176,249
Intellectual Property, Net [Member]
Current Assets
Intangible assets	$ 52,638	37,090
In-Process Research and Development [Member]
Current Assets
Intangible assets		$ 15,920